Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and D- and L-(β)-dideoxynucleoside triphosphate analogs

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 4, 2001, Pages 1192-1200

  Maga, G ^a   Hubscher U ^a   Pregnolato, M ^a   Ubiali, D ^a   Gosselin, G ^a   Spadari, S ^a  

^a CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYCYTIDINE 5' TRIPHOSPHATE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 2',3' DIDEOXYTHYMIDINE TRIPHOSPHATE; 3' AZIDO 2',3' DIDEOXYTHYMIDINE TRIPHOSPHATE; ANTIRETROVIRUS AGENT; DEOXYRIBONUCLEOTIDE; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DRUG CHOICE; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DNA REPLICATION; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MICROBIAL; DRUG SYNERGISM; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INHIBITORY CONCENTRATION 50; MUTATION; NEVIRAPINE; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; STEREOISOMERISM; THYMINE NUCLEOTIDES; ZIDOVUDINE;

EID: 0035080175     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.4.1192-1200.2001     Document Type: Article

References (39)

1. Kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-88204E
2. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy
3. A method for testing for synergy with any number of agents
4. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds
5. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors
6. Inhibition of HIV-1 reverse transcriptase by pyridinone derivatives. Potency, binding characteristics and effect of template sequence
7. Inhibition of HIV-1 reverse transcriptase by a quinazolinone and comparison with inhibition by pyridinones
8. Effect of resistance on combination chemotherapy for human immunodeficiency virus infection
9. Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors
10. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
11. Combination chemotherapy in vitro with adriamycin. Observations of additive, antagonistic and synergistic effects when used in two-drug combinations on cultured human lymphoma cells
12. Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5′-triphosphate β enantiomers of cytidine analogs
13. Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme
14. Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds
15. Anti-human immunodeficiency virus activity of the β-L-enantiomer of 2′,3′-dideoxycytidine and its 5-fluoro derivative in vitro
16. Fundamental concepts in the assessment of the joint interaction of biological response modifiers with other agents
17. The search for synergy: A critical review from a response surface perspective
18. Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants
19. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves
20. Human immunodeficiency virus type 1 reverse transcriptase
21. DNA replication and chemotherapy
22. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase
23. Effect of combinations: Mathematical basis of problem
24. Structural determinants of HIV-1 reverse transcriptase stereoselectivity towards (β)-L-deoxy- and dideoxy-pyrimidine nucleoside triphosphates: Molecular basis for the combination of L-dideoxynucleoside analogs with non-nucleoside inhibitors in anti-HIV chemotherapy
25. Molecular basis for the enantioselectivity of HIV-1 reverse transcriptase: Role of the 3′-hydroxyl group of the L-(β)-ribose in chiral discrimination between D- and L-enantiomers of deoxy- and dideoxy-nucleoside triphosphate analogs
26. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: Loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions
27. Selective interaction of the HIV-1 reverse transcriptase non-nucleoside inhibitor efavirenz and its thio-analog with different enzyme-substrate complexes
28. Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: The potential to use resistance data to guide clinical decisions
29. Sensitivity and resistance to (+)-calanolide A of wild type and mutated forms of HIV-1 reverse transcriptase
30. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine
31. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team
32. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene
33. A novel, highly enantioselective ketone alkynylation reaction mediated by chiral zinc aminoalkoxides
34. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2′-deoxy-3′-oxa-4′-thiocytidine, dOTC]
35. HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587
36. Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides
37. L-743,726 (DMP-266): A novel, highly potent nonnucleoside reverse transcriptase inhibitor of the human immunodeficiency virus type 1 reverse transcriptase
38. Selective and synergistic inhibition of human immuno-deficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442